MicroTech Medical (Hangzhou) Co., Ltd. announce that, on November 4, 2021, the National Medical Products Administration of China officially approved the registration of the "continuous glucose monitoring system" (AiDEX G7), an innovative product produced by the Company. AiDEX G7, the continuous glucose monitoring system of the Company (the "Product"), comprises a single-use glucose sensor, a glucose signal transmitter, a glucose signal receiver, glucose management software and accessories. It could be used by diabetes patients (aged 18 or above) to monitor the glucose level of subcutaneous interstitial fluid continuously or regularly. The Product is able to provide and store real-time glucose values for users to trace their glucose concentrations change and trends. Compared with other major continuous glucose monitoring systems in the market, the Product adopts core technologies including the current/impedance dual-mode monitoring technology with interference-rejecting electrode design and impedance-based auto-correction algorithms, high molecular-weight glucose permeable membrane polymer material synthesis technology, high-throughput sensor fabrication process and glucose oxidase curing process, and is the first of its kind in the People's Republic of China (the "PRC"). Its clinical advantage is that a single glucose sensor can provide up to 14 days of continuous glucose monitoring without the need of fingerstick blood glucose measurements for calibration. The Product was certified by the NMPA in May 2020 to be eligible for the Special Approval Procedures of Innovative Medical Devices promulgated by the NMPA. The results of the multi-center clinical study of the Product have been published previously, and its mean absolute relative difference (MARD) is 9.08% as compared to the venous blood reference value, which is at international leading level. The approval of the Product by the NMPA is another important breakthrough in innovative research and development product portfolio after the approval of Equil Patch Insulin Pump System by the NMPA. This represents a significant advancement in diabetes monitoring and treatment product portfolio. After obtaining marketing approval from the NMPA, the Company intends to commercialize the Product in the PRC and look forward to fully demonstrating the clinical advantages of the Product for the benefit of hundreds of millions of patients in China. This is a voluntary announcement made by the Company. The Company cannot guarantee that AiDEX G7 will ultimately be successfully marketed.